VSV-GP BI 1831169

{
  "id": "MLC-T-ONC-017543",
  "term": "VSV-GP BI 1831169",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant, live-attenuated, oncolytic chimeric virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus, and containing a genetically modified glycoprotein (GP), with potential immunomodulating and antineoplastic activities. Upon administration, VSV-GP BI 1831169 preferentially replicates in tumor cells. Due to defective antiviral host defense mechanisms in tumor cells, VSV-GP BI 1831169 is able to replicate in tumor cells without interference. This induces VSV-mediated cytolytic activity towards the tumor cells. In addition, viral infection stimulates the immune system to recognize these same tumor cells, leading to immune-mediated killing of both infected and non-infected tumor cells, thereby further killing tumor cells. In VSV-GP BI 1831169, the VSV-G glycoprotein is replaced with the Lymphocytic Choriomeningitis Virus glycoprotein in order to minimize the potential of neurotoxicity.",
  "synonyms": [
    "vesicular stomatitis virus-GP BI 1831169",
    "oncolytic virus BI 1831169",
    "oncolytic virus VSV-GP BI 1831169",
    "VSV-GP",
    "vesicular stomatitis virus-glycoprotein"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vsv-gp-bi-1831169/"
}